[go: up one dir, main page]

WO1998040375A3 - TRAITEMENT ASSOCIE UTILISANT DES BENZOTHIEPINES INHIBITRICES DU TRANSPORT ILEAL DE L'ACIDE BILIAIRE ET DES INHIBITEURS DE LA HMG Co-A REDUCTASE - Google Patents

TRAITEMENT ASSOCIE UTILISANT DES BENZOTHIEPINES INHIBITRICES DU TRANSPORT ILEAL DE L'ACIDE BILIAIRE ET DES INHIBITEURS DE LA HMG Co-A REDUCTASE Download PDF

Info

Publication number
WO1998040375A3
WO1998040375A3 PCT/US1998/003792 US9803792W WO9840375A3 WO 1998040375 A3 WO1998040375 A3 WO 1998040375A3 US 9803792 W US9803792 W US 9803792W WO 9840375 A3 WO9840375 A3 WO 9840375A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
benzothiepines
bile acid
reductase inhibitors
acid transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/003792
Other languages
English (en)
Other versions
WO1998040375A2 (fr
Inventor
David B Reitz
Len F Lee
Jinglin J Li
Horng-Chih Huang
Samuel J Tremont
Raymond E Miller
Shyamal C Baneriee
Robert E Manning
Kevin C Glenn
Bradley T Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998040375(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA002283575A priority Critical patent/CA2283575A1/fr
Priority to MXPA99008417A priority patent/MXPA99008417A/es
Priority to IL13187298A priority patent/IL131872A0/xx
Priority to JP53959498A priority patent/JP2002500628A/ja
Priority to BR9808013-0A priority patent/BR9808013A/pt
Priority to PL98336415A priority patent/PL336415A1/xx
Priority to EP98910075A priority patent/EP0971744A2/fr
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to AU64408/98A priority patent/AU730024C/en
Priority to SK1250-99A priority patent/SK125099A3/sk
Priority to HU0002395A priority patent/HUP0002395A3/hu
Priority to NZ337830A priority patent/NZ337830A/en
Publication of WO1998040375A2 publication Critical patent/WO1998040375A2/fr
Publication of WO1998040375A3 publication Critical patent/WO1998040375A3/fr
Priority to NO994390A priority patent/NO994390L/no
Anticipated expiration legal-status Critical
Priority to BG103793A priority patent/BG103793A/xx
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des benzothiépines, certains de leurs dérivés et de leurs analogues. L'invention concerne également des compositions contenant ces benzothiépines, dérivés et analogues. L'invention concerne enfin des procédés permettant d'utiliser ces composés et compositions dans des médicaments, en particulier pour la prophylaxie et le traitement d'états hyperlipidémiques tels que ceux qui sont liés chez les mammifères à l'athérosclérose ou l'hypercholestérolémie. L'invention concerne en outre des compositions et des procédés applicables dans un traitement associé utilisant des benzothiépines inhibitrices du transport iléal de l'acide biliaire et des inhibiteurs de la HMG Co-A réductase pour le traitement d'états hyperlipidémique.
PCT/US1998/003792 1997-03-11 1998-03-10 TRAITEMENT ASSOCIE UTILISANT DES BENZOTHIEPINES INHIBITRICES DU TRANSPORT ILEAL DE L'ACIDE BILIAIRE ET DES INHIBITEURS DE LA HMG Co-A REDUCTASE Ceased WO1998040375A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
NZ337830A NZ337830A (en) 1997-03-11 1998-03-10 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
AU64408/98A AU730024C (en) 1997-03-11 1998-03-10 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
IL13187298A IL131872A0 (en) 1997-03-11 1998-03-10 Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
JP53959498A JP2002500628A (ja) 1997-03-11 1998-03-10 回腸胆汁酸輸送阻害ベンゾチエピンおよびＨＭＧ Ｃｏ−Ａレダクターゼ阻害剤を用いた併用療法
BR9808013-0A BR9808013A (pt) 1997-03-11 1998-03-10 Terapia de combinação empregando benzotiepinas de inibição de transporte de ácido biliar ileal e inibidores de redutase de hmg co-a
PL98336415A PL336415A1 (en) 1997-03-11 1998-03-10 Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors
EP98910075A EP0971744A2 (fr) 1997-03-11 1998-03-10 TRAITEMENT ASSOCIE UTILISANT DES BENZOTHIEPINES INHIBITRICES DU TRANSPORT ILEAL DE L'ACIDE BILIAIRE ET DES INHIBITEURS DE LA HMG Co-A REDUCTASE
CA002283575A CA2283575A1 (fr) 1997-03-11 1998-03-10 Traitement associe utilisant des benzothiepines inhibitrices du transport ileal de l'acide biliaire et des inhibiteurs de la hmg co-a reductase
SK1250-99A SK125099A3 (en) 1997-03-11 1998-03-10 Combination of ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
HU0002395A HUP0002395A3 (en) 1997-03-11 1998-03-10 Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
MXPA99008417A MXPA99008417A (es) 1997-03-11 1998-03-10 Terapia de combinacion que emplaza benzotiepinas inhibidoras de transporte de acido biliar ileal e inhibidores de hmg co-a reductasa.
NO994390A NO994390L (no) 1997-03-11 1999-09-10 Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorer
BG103793A BG103793A (en) 1997-03-11 1999-10-11 COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4066097P 1997-03-11 1997-03-11
US60/040,660 1997-03-11

Publications (2)

Publication Number Publication Date
WO1998040375A2 WO1998040375A2 (fr) 1998-09-17
WO1998040375A3 true WO1998040375A3 (fr) 1998-12-03

Family

ID=21912237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003792 Ceased WO1998040375A2 (fr) 1997-03-11 1998-03-10 TRAITEMENT ASSOCIE UTILISANT DES BENZOTHIEPINES INHIBITRICES DU TRANSPORT ILEAL DE L'ACIDE BILIAIRE ET DES INHIBITEURS DE LA HMG Co-A REDUCTASE

Country Status (16)

Country Link
EP (1) EP0971744A2 (fr)
JP (1) JP2002500628A (fr)
CN (1) CN1255864A (fr)
AU (1) AU730024C (fr)
BG (1) BG103793A (fr)
BR (1) BR9808013A (fr)
CA (1) CA2283575A1 (fr)
HU (1) HUP0002395A3 (fr)
IL (1) IL131872A0 (fr)
MX (1) MXPA99008417A (fr)
NO (1) NO994390L (fr)
NZ (1) NZ337830A (fr)
PL (1) PL336415A1 (fr)
RU (1) RU2247579C2 (fr)
SK (1) SK125099A3 (fr)
WO (1) WO1998040375A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
US6890958B2 (en) 1998-12-23 2005-05-10 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
US6943189B2 (en) 1994-09-13 2005-09-13 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors
US11844822B2 (en) 2014-06-25 2023-12-19 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU2003241629B2 (en) * 1999-04-19 2005-06-16 Astrazeneca Ab An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002051396A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions pharmaceutiques contenant des derives de cyclobutene
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
RU2305681C2 (ru) 2001-09-08 2007-09-10 Астразенека Аб Производные бензотиадиазепина, способ их получения (варианты)
RU2004121898A (ru) 2001-12-19 2006-01-20 Атеродженикс, Инк. (Us) Производные халкона и их применение для лечения заболеваний
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
CN100494185C (zh) * 2002-08-28 2009-06-03 旭化成制药株式会社 新型季铵化合物
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP4711953B2 (ja) 2004-02-27 2011-06-29 旭化成ファーマ株式会社 新規なベンゾチアゼピン及びベンゾチエピン化合物
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
DK2637668T3 (en) 2010-11-04 2016-08-29 Albireo Ab Ibat inhibitors for the treatment of liver diseases
DK2637646T3 (en) 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
MX382960B (es) 2011-10-28 2025-03-13 Shire Human Genetic Therapies Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
CA2907214A1 (fr) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Inhibiteurs de recyclage d'acide biliaire pour le traitement de l'ƒsophage de barrett et du reflux gastroƒsophagien pathologique
KR20230152818A (ko) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106794188B (zh) 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017138877A1 (fr) 2016-02-09 2017-08-17 Albireo Ab Formulation orale de cholestyramine et utilisation associée
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
ES2874546T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
EP3664782B1 (fr) 2017-08-09 2025-01-29 Albireo AB Pastilles de cholestyramine, formulations orales de cholestyramine et leur utilisation médicale
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
UA128761C2 (uk) 2018-06-20 2024-10-16 Альбірео Аб Кристалічні модифікації одевіксибату
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
EP3883570A4 (fr) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
EP3921027B1 (fr) 2019-02-06 2023-07-19 Albireo AB Composés de benzothiazépine et leur utilisation en tant que modulateurs de l'acide biliaire
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HRP20230039T1 (hr) 2019-02-06 2023-06-09 Albireo Ab Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina
AU2020221834B2 (en) 2019-02-12 2025-10-23 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2021110885A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothiadiazépine et leur utilisation en tant que modulateurs de l'acide biliaire
CA3158184A1 (fr) 2019-12-04 2021-08-10 Albireo Ab Composes de benzothiadiazepine et leur utilisation en tant que modulateurs de l'acide biliaire
WO2021110883A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs de l'acide biliaire
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
WO2021110887A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothiazépine et leur utilisation en tant que modulateurs de l'acide biliaire
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
JP7748451B2 (ja) 2020-08-03 2025-10-02 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN112274648B (zh) * 2020-11-23 2022-10-14 郑州大学 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法
KR20230117393A (ko) 2020-12-04 2023-08-08 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2025524362A (ja) 2022-06-09 2025-07-30 アルビレオ・アクチボラグ 肝炎の処置
TW202423921A (zh) * 2022-08-22 2024-06-16 美商安塔製藥公司 稠合的雜雙環抗病毒劑
WO2025146508A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire
WO2025146507A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
NZ245503A (en) * 1991-12-20 1995-11-27 Hoechst Ag Polymers containing bile acids; pharmaceuticals and preparatory methods
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, 1227 (3). 1994. 137-154. *
BIOLOGICAL ABSTRACTS, vol. 11, Philadelphia, PA, US; abstract no. 317019, WESS G ET AL: "Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors: The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system" XP002078626 *
BIOLOGICAL ABSTRACTS, vol. 11, Philadelphia, PA, US; abstract no. 489744, KRAMER W ET AL: "Bile acid derived HMG-CoA reductase inhibitors" XP002078625 *
JOURNAL OF MEDICINAL CHEMISTRY, 37 (20). 1994. 3240-3246. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943189B2 (en) 1994-09-13 2005-09-13 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors
US6890958B2 (en) 1998-12-23 2005-05-10 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
US11844822B2 (en) 2014-06-25 2023-12-19 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof

Also Published As

Publication number Publication date
RU2247579C2 (ru) 2005-03-10
AU6440898A (en) 1998-09-29
MXPA99008417A (es) 2005-02-03
WO1998040375A2 (fr) 1998-09-17
JP2002500628A (ja) 2002-01-08
IL131872A0 (en) 2001-03-19
CN1255864A (zh) 2000-06-07
PL336415A1 (en) 2000-06-19
NZ337830A (en) 2001-07-27
HUP0002395A3 (en) 2002-12-28
BG103793A (en) 2000-07-31
NO994390L (no) 1999-11-04
AU730024C (en) 2004-08-05
EP0971744A2 (fr) 2000-01-19
BR9808013A (pt) 2001-09-25
NO994390D0 (no) 1999-09-10
AU730024B2 (en) 2001-02-22
SK125099A3 (en) 2001-02-12
CA2283575A1 (fr) 1998-09-17
HUP0002395A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
WO1998040375A3 (fr) TRAITEMENT ASSOCIE UTILISANT DES BENZOTHIEPINES INHIBITRICES DU TRANSPORT ILEAL DE L'ACIDE BILIAIRE ET DES INHIBITEURS DE LA HMG Co-A REDUCTASE
AP2001002062A0 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake.
IL126038A0 (en) Novel benzothiepines and derivatives thereof and pharmaceutical compositions comprising them
GR3035583T3 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
AU6958996A (en) Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
EP1334719A3 (fr) Pentafluorobenzenesulfonamides et analogues
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
EP0807633A3 (fr) (5,6)-Pyrimidin-4-ones condensées à hétéroaryle, substituées en 2,3
AU689817B2 (en) Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof
TW268937B (fr)
AU4133997A (en) Pharmaceutical composition for the treatment of syndrome x of reaven
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
AU3481795A (en) Pharmaceutical compositions containing d2o
AU5816496A (en) Process for the depyrogenation of injectable pharmaceutical solutions
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
AU4644299A (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosisand treatment of anti-phospholipid syndrome
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AU6187394A (en) New pyrrolopyrazine compounds, processes for their preparation and the pharmaceutical compositions which contain them
AU5522794A (en) New angiopeptin cyclopeptide compounds, process for the preparation thereof, and pharmaceutical compositios containing them
AU6970394A (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
ES2134128A1 (es) Un procedimiento de reduccion de los niveles residuales de disolventes, presentes en las composiciones farmaceuticas, en particular en los antibioticos y antibioticos obtenidos segun el mismo.
IT1265045B1 (it) Composizione farmaceutica atta a inibire la sintesi della lipoproteina (a)
HK1033456A (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131872

Country of ref document: IL

Ref document number: 98804995.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2283575

Country of ref document: CA

Ref document number: 2283575

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 125099

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1019997008341

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 539594

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008417

Country of ref document: MX

Ref document number: 64408/98

Country of ref document: AU

Ref document number: PV1999-3228

Country of ref document: CZ

Ref document number: 99-00975

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 337830

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1998910075

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998910075

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-3228

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997008341

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 64408/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: PV1999-3228

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019997008341

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998910075

Country of ref document: EP